<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15271">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908074</url>
  </required_header>
  <id_info>
    <org_study_id>MBGS206</org_study_id>
    <nct_id>NCT02908074</nct_id>
  </id_info>
  <brief_title>A 6 Month Safety Extension Study of MBGS205 Evaluating the Long Term Effects of BGS649 on Bone Mineral Density</brief_title>
  <official_title>A 6 Month, Double-blind Safety Extension Study of MBGS205 Evaluating the Effects of Long Term Treatment With BGS649 on Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mereo BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6 months, active treatment, extension study, open to subjects who have completed
      full 24 weeks in Study MBGS205 (A Phase IIb multicentre, double-blind, dose-ranging,
      randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese
      subjects with hypogonadotropic hypogonadism [HH]).The main purpose of Study MBGS206 is to
      evaluate bone mineral density and other long term safety and efficacy parameters in subjects
      after 12 months exposure with BGS649.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in lumbar bone mineral density measured by DEXA (g/cm2) from Baseline in Study MBGS205 to Week 48 in Study MBGS206 by dose group in subjects randomised to active treatment in Study MBGS205.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Experimental: Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BGS649 Dose 1 weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BGS649 Dose 2 weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BGS649 Dose 3 weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGS649</intervention_name>
    <description>Capsules will be taken weekly for a maximum of 24 weeks</description>
    <arm_group_label>Experimental: Regimen 1</arm_group_label>
    <arm_group_label>Experimental: Regimen 2</arm_group_label>
    <arm_group_label>Experimental: Regimen 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participating in Study MBGS205 and completion of the 24 week treatment period without
             meeting any discontinuation criteria of Study MBGS205

          -  In opinion of the investigator has been compliant with the requirements of the Study
             MBGS205 protocol.

        Exclusion Criteria:

        -Meeting any of the discontinuation criteria of initial Study MBGS205
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Jones</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barnsley Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>September 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadotropic</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
